-- Online-First Publication Currently Available -- -- First Randomized Trial With Survival Endpoint in Second-Line Myelodysplastic Syndromes (MDS) -- -- New Phase 3 "INSPIRE" Study of IV Rigosertib Currently Enrolling Patients -- NEWTOWN, Pa., March 09, 2016 (GLOBE NEWSWIRE) -- Onconova
NEWTOWN, Pa., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting
NEWTOWN, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company will host a Key Opinion Leader breakfast focused on the
--Combination Achieved 77% Overall Response Rate in all MDS Patients-- --Overall Response Rate of 84% in treatment-naïve MDS Patients-- --Response Rate of 64% in MDS Patients who had Previously Failed HMAs-- --Company to Provide Further Information on Next Steps for Combination Development
